Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

To begin shipping private-label equivalents of Miles' Alka-Seltzer Plus cold, cough & cold, and nighttime cold medicine in liquid gelcaps by early 1995. The company also plans to introduce in January 1995 Multi-Symptom Plus cough remedy for children in packages of 24 chewable cherry tablets and four-ounce bottles of cherry liquid. Both compare to Tylenol cold. Perrigo will launch a maximum strength non-aspirin flu medication modeled after Tylenol Flu Night Time in early 1995 in packages of 20 gelcaps. In December, Perrigo will introduce Diphadryl, a private- label version of Warner Wellcome's Benadryl complete allergy medication that will be available in packages of 24 softgels. During the upcoming cold/flu season, Perrigo expects to introduce Diphedryl allergy/sinus/headache formula (24 caplets), dye-free allergy formula (diphenhydramine HCl) in 24 clear liquid gelcaps, and a four-ounce alcohol-,sugar-and dye-free elixir (diphenhydramine HCl) in 12 pediatric doses. Perrigo recently began shipping a 72-tablet, private-label equivalent to Tums Ultra Strength in assorted fruit flavors. In early 1995, Perrigo's entire analgesic category in gelcaps and caplets will be available with twist-cap packaging similar to the Tylenol Fast-Cap and Advil Easy-Open-Cap
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel